Global Information
회사소개 | 문의 | 비교리스트

항염증 : 역학 인사이트(-2030년)

Anti-inflammatory - Epidemiology Insight - 2030

리서치사 DelveInsight Business Research LLP
발행일 On Demand Report 상품코드 966752
페이지 정보 영문 100 Pages 배송안내 2-10일 (영업일 기준)
가격
US $ 3,750 ₩ 4,778,000 PDF (Single User License)
US $ 7,500 ₩ 9,556,000 PDF (Site License)
US $ 11,250 ₩ 14,334,000 PDF (Global License)


항염증 : 역학 인사이트(-2030년) Anti-inflammatory - Epidemiology Insight - 2030
발행일 : On Demand Report 페이지 정보 : 영문 100 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

미국, 유럽 5개국(독일, 스페인, 이탈리아, 프랑스, 영국) 및 일본 7개 주요 시장의 항염증 시장에 대해 상세하게 설명했으며, 질환 배경과 개요, 미충족 수요, 각국의 역학, 치료법 등에 관한 정보를 제공합니다.

목차

제1장 주요 인사이트

제2장 주요 요약

제3장 항염증 : 질환 배경과 개요

  • 서론
  • 징조와 증상
  • 병태생리학
  • 위험인자
  • 진단

제4장 환자 여정

제5장 역학과 환자 인구

  • 역학 주요 조사 결과
  • 가정과 이론적 근거 : 주요 7개국
  • 역학 시나리오 : 주요 7개국
    • 주요 7개국의 항염증 역학 시나리오
  • 미국의 역학
    • 미국의 항염증 역학 시나리오
  • 유럽 5개국의 역학 : 국가별
    • 독일의 역학
    • 프랑스의 역학
    • 이탈리아의 역학
    • 스페인의 역학
    • 영국의 역학
  • 일본의 역학
    • 일본의 항염증 역학 시나리오

제6장 치료 알고리즘, 현재 치료 및 의료 행위

  • 항염증 치료와 관리
  • 항염증 치료 알고리즘

제7장 KOL의 견해

제8장 미충족 수요

제9장 부록

  • 참고문헌
  • 보고서 조사 방법

제10장 DelveInsight 서비스 내용

제11장 면책사항

제12장 DelveInsight 소개

KSM 20.11.04

List of Tables

  • Table 1: Anti-inflammatory Epidemiology in 7MM (2017-2030)
  • Table 2: Anti-inflammatory Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Anti-inflammatory Epidemiology in the United States (2017-2030)
  • Table 4: Anti-inflammatory Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Anti-inflammatory Epidemiology in Germany (2017-2030)
  • Table 6: Anti-inflammatory Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Anti-inflammatory Epidemiology in France (2017-2030)
  • Table 8: Anti-inflammatory Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Anti-inflammatory Epidemiology in Italy (2017-2030)
  • Table 10: Anti-inflammatory Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Anti-inflammatory Epidemiology in Spain (2017-2030)
  • Table 12: Anti-inflammatory Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Anti-inflammatory Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Anti-inflammatory Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Anti-inflammatory Epidemiology in Japan (2017-2030)
  • Table 16: Anti-inflammatory Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Anti-inflammatory Epidemiology in 7MM (2017-2030)
  • Figure 2: Anti-inflammatory Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Anti-inflammatory Epidemiology in the United States (2017-2030)
  • Figure 4: Anti-inflammatory Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Anti-inflammatory Epidemiology in Germany (2017-2030)
  • Figure 6: Anti-inflammatory Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Anti-inflammatory Epidemiology in France (2017-2030)
  • Figure 8: Anti-inflammatory Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Anti-inflammatory Epidemiology in Italy (2017-2030)
  • Figure 10: Anti-inflammatory Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Anti-inflammatory Epidemiology in Spain (2017-2030)
  • Figure 12: Anti-inflammatory Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Anti-inflammatory Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Anti-inflammatory Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Anti-inflammatory Epidemiology in Japan (2017-2030)
  • Figure 16: Anti-inflammatory Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report

DelveInsight's 'Anti-inflammatory - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Anti-inflammatory epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Anti-inflammatory Understanding

The DelveInsight Anti-inflammatory epidemiology report gives a thorough understanding of the Anti-inflammatory by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Anti-inflammatory in the US, Europe, and Japan. The report covers the detailed information of the Anti-inflammatory epidemiology scenario in seven major countries (US, EU5, and Japan).

Anti-inflammatory Epidemiology Perspective by DelveInsight

The Anti-inflammatory epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Anti-inflammatory epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Anti-inflammatory epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Anti-inflammatory Detailed Epidemiology Segmentation

The Anti-inflammatory epidemiology covered in the report provides historical as well as forecasted Anti-inflammatory epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Anti-inflammatory report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Anti-inflammatory report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Anti-inflammatory Epidemiology Report and Model provide an overview of the risk factors and global trends of Anti-inflammatory in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Anti-inflammatory in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Anti-inflammatory
  • The report provides the segmentation of the Anti-inflammatory epidemiology

Report Highlights:

  • 11-Year Forecast of Anti-inflammatory epidemiology
  • 7MM Coverage
  • Total Cases of Anti-inflammatory
  • Total Cases of Anti-inflammatory according to segmentation
  • Diagnosed cases of Anti-inflammatory

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anti-inflammatory?
  • What are the key findings pertaining to the Anti-inflammatory epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Anti-inflammatory across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Anti-inflammatory?
  • What are the currently available treatments of Anti-inflammatory?

Reasons to buy:

  • The Anti-inflammatory Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Anti-inflammatory market
  • Quantify patient populations in the global Anti-inflammatory market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Anti-inflammatory therapeutics in each of the markets covered
  • Understand the magnitude of Anti-inflammatory population by its epidemiology
  • The Anti-inflammatory Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Anti-inflammatory

3. Anti-inflammatory : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Anti-inflammatory Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Anti-inflammatory Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Anti-inflammatory Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Anti-inflammatory Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Anti-inflammatory Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Anti-inflammatory Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Anti-inflammatory Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Anti-inflammatory Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Anti-inflammatory Treatment and Management
  • 6.2. Anti-inflammatory Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

Back to Top
전화 문의
F A Q